- Home
- NCPL vs EVOK Comparison
NCPL vs EVOK Comparison
Compare NCPL & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- EVOK
- Stock Information
- Founded
- NCPL 1984
- EVOK 2007
- Country
- NCPL United States
- EVOK United States
- Employees
- NCPL N/A
- EVOK N/A
- Industry
- NCPL Investment Managers
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- EVOK Health Care
- Exchange
- NCPL Nasdaq
- EVOK Nasdaq
- Market Cap
- NCPL 4.3M
- EVOK 4.2M
- IPO Year
- NCPL N/A
- EVOK 2013
- Fundamental
- Price
- NCPL $6.10
- EVOK $2.61
- Analyst Decision
- NCPL
- EVOK
- Analyst Count
- NCPL 0
- EVOK 0
- Target Price
- NCPL N/A
- EVOK N/A
- AVG Volume (30 Days)
- NCPL 907.7K
- EVOK 19.3K
- Earning Date
- NCPL 07-28-2025
- EVOK 08-12-2025
- Dividend Yield
- NCPL N/A
- EVOK N/A
- EPS Growth
- NCPL N/A
- EVOK N/A
- EPS
- NCPL N/A
- EVOK N/A
- Revenue
- NCPL $812,612.00
- EVOK $11,594,083.00
- Revenue This Year
- NCPL N/A
- EVOK $57.82
- Revenue Next Year
- NCPL $101.16
- EVOK $59.12
- P/E Ratio
- NCPL N/A
- EVOK N/A
- Revenue Growth
- NCPL N/A
- EVOK 89.89
- 52 Week Low
- NCPL $1.41
- EVOK $1.94
- 52 Week High
- NCPL $11.90
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- NCPL 66.76
- EVOK 41.11
- Support Level
- NCPL $5.25
- EVOK $2.50
- Resistance Level
- NCPL $8.75
- EVOK $2.84
- Average True Range (ATR)
- NCPL 1.18
- EVOK 0.19
- MACD
- NCPL 0.31
- EVOK -0.00
- Stochastic Oscillator
- NCPL 71.60
- EVOK 34.67
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.